Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price was up 10.8% during trading on Monday . The stock traded as high as $6.97 and last traded at $6.97. Approximately 16,386 shares changed hands during trading, a decline of 99% from the average daily volume of 1,199,597 shares. The stock had previously closed at $6.29.
A number of equities research analysts have recently issued reports on AUTL shares. Zacks Investment Research raised shares of Autolus Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Monday, August 2nd. Mizuho restated a “buy” rating and issued a $18.00 target price on shares of Autolus Therapeutics in a research report on Monday, August 2nd. Finally, Jefferies Financial Group raised shares of Autolus Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from $6.00 to $12.00 in a research note on Monday, June 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $13.43.
The stock’s fifty day moving average is $6.27 and its 200 day moving average is $6.27. The company has a market capitalization of $501.93 million, a P/E ratio of -2.66 and a beta of 1.72.
Several hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC raised its holdings in Autolus Therapeutics by 162.7% in the second quarter. Lindbrook Capital LLC now owns 7,882 shares of the company’s stock worth $52,000 after purchasing an additional 4,882 shares in the last quarter. HRT Financial LP purchased a new stake in Autolus Therapeutics in the first quarter valued at approximately $62,000. Tudor Investment Corp Et Al purchased a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $93,000. Deutsche Bank AG acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth approximately $99,000. Finally, XTX Topco Ltd acquired a new stake in shares of Autolus Therapeutics in the 2nd quarter worth $101,000. Hedge funds and other institutional investors own 33.54% of the company’s stock.
Autolus Therapeutics Company Profile (NASDAQ:AUTL)
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.
Featured Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.